WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Neurocrine Biosciences earnings were $478.6M for the trailing 12 months ending Dec 31, 2025, with 41.5% growth year over year. The latest NBIX earnings report on Dec 31, 2025 announced Q4 2025 earnings of $153.7M, down 26.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NBIX reported annual earnings of $478.6M, with 40.2% growth.

NBIX past earnings growth

How has NBIX's earnings growth performed historically?

Company
41.47%
Industry
46.11%
Market
45.55%
NBIX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NBIX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NBIX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NBIX earnings history

Current Revenue
$2.9B
Current Earnings
$478.6M
Current Profit Margin
16.7%

NBIX Return on Equity

Current Company
16.7%
Current Industry
14.3%
Current Market
30.2%
NBIX's Return on Equity (16.7%)... subscribe to Premium to read more.
High Return on Equity Performance

NBIX Return on Assets

Current Company
11.6%
Current Industry
5.4%
NBIX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NBIX announces earnings.

NBIX Return on Capital Employed

Current Company
18.14%
Current Industry
12.1%
NBIX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBIX vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NBIX$762.30M$478.60M+1.89%$4.81
RGC-$3.19M-$3.58MN/A-$0.01
ELAN$676.00M-$232.00MN/A-$0.47
RDY$1.12B$657.56M+20.54%$0.79
VTRS-$395.40M-$3.51BN/A-$3.00
View Top Pharmaceutical Stocks

Neurocrine Biosciences Earnings Reports & History FAQ

What were Neurocrine Biosciences's earnings last quarter?

On NBIX's earnings call on Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 2025 earnings per share (EPS) of $1.54, up 49.51% year over year. Total NBIX earnings for the quarter were $153.70 million. In the same quarter last year, Neurocrine Biosciences's earnings per share (EPS) was $1.03.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

Is Neurocrine Biosciences profitable or losing money?

As of the last Neurocrine Biosciences earnings report, Neurocrine Biosciences is currently profitable. Neurocrine Biosciences's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $478.60 million, a 40.23% increase year over year.

What was NBIX's earnings growth in the past year?

As of Neurocrine Biosciences's earnings date in Invalid Date, Neurocrine Biosciences's earnings has grown 41.47% year over year. This is 4.64 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 46.11%. NBIX earnings in the past year totalled $478.60 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.